Article

Updates in the Treatment of Mantle Cell Lymphoma

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Related Videos
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
Manali Kamdar, MD, of University of Colorado Anschutz School of Medicine
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Bendamustine/Obinutuzumab Induction in MCL
November 18th 2024

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML